$15 Billion Myland Offer Rejected By Actavis

Source: PharmaManufacturing.com

May 16, 2013

Bloomberg.com

Actavis Inc. rejected a cash-and-stock offer from fellow generic drugmaker Mylan Inc. for $15 billion, deciding instead to pursue talks to take over Warner Chilcott (WCRX) Plc, said people familiar with the matter.
The Mylan offer valued Actavis at $120 a share and would have created the world’s largest generic drugmaker, said  sources, who asked not to be named because the discussions were private. It is reported that Mylan and Warner Chilcott both approached Actavis in recent weeks to discuss potential deals when news of merger talks with Valeant Pharmaceuticals International Inc. leaked. Read the full story.
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments